Saturday, April 1, 2017

MRI and TRUS biopsy in prostate cancer

A paper by Ahmed et al published in the Lancet suggests a quarter of men suspected of having prostate cancer could avoid potentially dangerous biopsies with the help of MRI scans.

The authors did a multicenter study and tested the diagnostic accuracy of Multi-parametric MRI (MP-MRI) and Transrectal ultrasound guided prostate biopsy (TRUS-biopsy) against template prostate mapping biopsy (TPM-biopsy). Men with prostate-specific antigen concentrations up to 15 ng/mL, with no previous biopsy, underwent 1·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy.  

The researchers enrolled 740 men, 576 of who underwent 1·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsies.  Results from TPM-biopsy showed 408 (71%) of the men had cancer, including 230 (40%) men with clinically significant cancer.  When evaluating the 230 men with clinically significant cancer, the MP-MRI had correctly diagnosed 93% of the aggressive cancers, whereas TRUS-biopsy diagnosed only 48% as aggressive. This indicated that MP-MRI was more sensitive than TRUS-biopsy (P < .0001).  Of the 10 men with a negative MP-MRI scan, nine (89%) had no cancer or a harmless cancer.

However, TRUS-biopsy had greater specificity (96% vs. 41%) and positive predictive value (90% vs. 51%; P < .0001 for both) than MP-MRI.  Forty-four (5·9%) of 740 patients reported serious adverse events, including 8 cases of sepsis following biopsy.

This study shows that using the two tests could reduce overdiagnosis of harmless cancers by 5%, prevent one in four men from having an unnecessary biopsy, and improve the detection of aggressive cancers from 48% to 93%.


In conclusion given that prostatic cancer which is the most common cancer in men with about 176,000 new cases and the cause of death in 27,000 patients in the United States in 2013, MP-MRI is a promising diagnostic test in the effort to reducing over-diagnosis of clinically insignificant prostate cancers while improving the detection of clinically significant cancers.

Wednesday, March 1, 2017

Low Dose CT Lung Cancer Screening

Research by Kinsinger et al published in JAMA Internal Medicine revealed that “low dose CT scans” frequently produce false positives and demand considerable effort by both patients and requesting physicians.

The US Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose computed tomography for current and former heavy smokers aged 55 to 80 years.

This clinical demonstration study was conducted at 8 academic VHA hospitals among 93 033 who met the criteria for LCS, 2106 agreed to undergo screening (2028 were men and 78 women; mean [SD] age, 64.9 [5.1] years).

Wide variation in processes and patient experiences occurred among the 8 sites. Of the 2106 patients screened, 1257 (59.7%) had nodules; 1184 of these patients (56.2%) required tracking, 42 (2.0%) required further evaluation but the findings were not cancer, and 31 (1.5%) had lung cancer. A variety of incidental findings, such as emphysema, other pulmonary abnormalities, and coronary artery calcification, were noted on the scans of 857 patients (40.7%).


In conclusion the research, conducted in more than 2000 high-risk VHA patients aged 55 to 80 years found lung cancer in 1.5% of patients, but around 60% of individuals who were screened had 1 or more nodules that required follow up. In addition, incidental findings were reported in around 40% of patients. It is estimated that implementation of LCS in the VHA 6.7 million patients will lead to approximately 900000 patients being eligible for LCS and will require substantial clinical effort for both patients and staff.

Wednesday, February 1, 2017

How effective is screening mammography?

A study by Welch et al published in New Engl J Med added to the growing evidence that for every woman who was helped by screening mammography many have been harmed.

The authors used data from the SEER program from 1975 through 2012. They calculated the size-specific cancer case fatality rate in women 40 year old and older for two time periods: a baseline period before the implementation of widespread screening mammography (1975 through 1979) and a period encompassing 10 years (2000 through 2002).

Screening did result in more cancers being detected, with invasive tumors measuring <2 cm or in situ carcinomas increased from 36% to 68%; and the detected tumors that were large, which were invasive cancers and measuring ≥2 cm decreased from 64% to 32%.  Surprisingly though the data suggest that only about 30 of the 162 additional small tumors per 100,000 women that screening mammograms found would ever have progressed to a dangerous stage. That means that 132, or 81 percent, of the 162 extra tumors detected represented overdiagnosis, that resulted to treatment of tumors that were never destined to harm.

Most importantly, the incidence of metastatic cancer, which is the type that causes most deaths, was flat. 

In conclusion the findings from this study indicate that screening mammography finds many small cancers the dogma that all will grow, metastasize resulting in fatality is questionable. The authors also suggest that although screening may decrease cancer mortality as reflected by the declining incidence of larger tumors, they believe that the two thirds reduction in breast cancer mortality is due to recent advances in treatment. 


N Engl J Med 2016; 375:1438-1447

Sunday, January 1, 2017

Top Three Posts

In the past three years I uploaded 101 posts in Radiology Weekly.  The top three in order of viewing frequency were:

Risk of Stroke due to Intracranial Atherosclerosis


iPad is Accurate in the Diagnosis of Bone Fractures


Circulating Tumor Cells Culture Promises Individualized Testing and Treatment 


Most visitors to my blog were from United States, Greece, Russia, France, Poland, Ukraine, Turkey, United Kingdom, Ireland and China in that order. 

I am sure some of you have noticed that I am not true to my original intention of posting weekly.  Starting with this post and into the future I will continue uploading on the 1st of each  month. 


I wish you all and your families a Happy New Year.

Thursday, December 15, 2016

Preoperative Breast MRI detects additional cancers

A paper by Bae et al published in Radiology indicates that preoperative MRI in women whose breast cancer was detected by ultrasound found additional cancers.

The study was a retrospective review of 374 women, median age, 48 years, with breast cancer detected at screening ultrasound.

Of 374 women, 21 or 5.6% patients were diagnosed with additional cancer.  In premenopausal women with invasive breast cancer and in those with index invasive lobular histologic type had higher incidence of additional cancer detected at MR imaging.  Premenopausal status also put the women at risk.


The authors concluded that preoperative MRI detected additional sites of cancer in women with breast cancer detected at screening ultrasound.

Thursday, December 1, 2016

Ultrasound is ineffective in the healing of bone fractures

A study published in the BMJ suggests that low-intensity pulsed ultrasound, used to speed healing of bone fractures, may be ineffective.

A randomized clinical trial that involved 501 patients who had surgical repair of fractures of the tibia found that patients treated with the low-intensity pulsed ultrasound (LIPUS) healed at the same rate as those given a sham treatment.

Patients self administer daily LIPUS (n=250) or use a sham device (n=251) until their tibial fracture showed radiographic healing or until one year after intramedullary fixation.

Primary registry specified outcome was time to radiographic healing within one year of fixation; secondary outcome was rate of non-union. Additional protocol specified outcomes included short form-36 (SF-36) physical component summary (PCS) scores, return to work, return to household activities, return to ≥80% of function before injury, return to leisure activities, time to full weight bearing, scores on the health utilities index (mark 3), and adverse events related to the device.

Results showed no impact on SF-36 PCS scores between LIPUS and control groups or for the interaction between time and treatment; minimal important difference is 3-5 points or in other functional measures. There was also no difference in time to radiographic healing. There were no differences in safety outcomes between treatment groups. Patient compliance was moderate; 73% of patients administered ≥50% of all recommended treatments.


It was concluded that postoperative use of LIPUS after tibial fracture fixation does not accelerate radiographic healing and fails to improve functional recovery.